LOS ANGELES, Feb. 11, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Anthony J. Cataldo has been named President and Chief Executive Officer. Mr. Cataldo succeeds Robert Brooke, who now serves as a strategic advisor to Genesis Biopharma. In addition, the Company named Michael Handelman as Chief Financial Officer, Treasurer and Secretary, succeeding Richard McKilligan.
Mr. Cataldo and Mr. Handelman have been appointed to the Company's Board of Directors. Mr. Brooke, Mr. McKilligan and Mark Ahn have resigned as members of the Genesis Biopharma Board. All of these changes are effective immediately.
"I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value," said Mr. Cataldo. "Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralizes a key cancer defense mechanism that is over-expressed in more than 80% of tumors. The anti-CD55 technology could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development."
Mr. Cataldo, age 58, has nearly two decades experience as a senior executive with publicly traded companies. He currently serves as the Chairman, Chief Executive Officer and a Director of Oxis International, Inc. (OTC Bulletin Board: OXIS), positions he has held since March 2009. Oxis is engaged in the research, development and sale of products that counteract the harmful effects of oxidative st
|SOURCE Genesis Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved